Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
or
Menu

Akebia Therapeutics (AKBA)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ fieldTitles[key] ]] [[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 364,607
  • Shares Outstanding, K 57,059
  • Annual Sales, $ 177,980 K
  • Annual Income, $ -76,910 K
  • 36-Month Beta 1.48
  • Price/Sales 1.43
  • Price/Cash Flow N/A
  • Price/Book 2.52
  • Price/Earnings ttm 0.00
  • Earnings Per Share ttm -1.29
  • Most Recent Earnings N/A on N/A
  • Next Earnings Date 03/11/19
  • Annual Dividend & Yield 0.00 (0.00%)
  • Most Recent Dividend N/A on N/A
  • Sectors:

    Medical - Drugs

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 6 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/18
See More
  • Average Estimate -0.41
  • Number of Estimates 2
  • High Estimate -0.29
  • Low Estimate -0.52
  • Prior Year 0.25
  • Growth Rate Est. (year over year) -264.00%

Price Performance

See More
Period Period Low Period High Performance
1-Month
5.20 +22.88%
on 12/24/18
6.98 -8.45%
on 12/19/18
-0.10 (-1.54%)
since 12/18/18
3-Month
5.20 +22.88%
on 12/24/18
10.45 -38.85%
on 12/13/18
-2.37 (-27.05%)
since 10/18/18
52-Week
5.20 +22.88%
on 12/24/18
15.78 -59.51%
on 01/29/18
-8.27 (-56.41%)
since 01/18/18

Most Recent Stories

More News
Akebia Therapeut Shares Down 7.5% Since SmarTrend's Sell Call (AKBA)

SmarTrend identified a Downtrend for Akebia Therapeut (NASDAQ:AKBA) on December 19th, 2018 at $6.64. In approximately 4 weeks, Akebia Therapeut has returned 7.53% as of today's recent price of $6.14.

AKBA : 6.39 (+1.43%)
Akebia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Akebia Therapeutics, Inc. (Nasdaq: AKBA), a biopharmaceutical company focused on the development and commercialization of therapeutics for patients with kidney disease, granted six...

AKBA : 6.39 (+1.43%)
Akebia Therapeutics to Present at the 37th Annual J.P. Morgan Healthcare Conference

Akebia Therapeutics, Inc. (Nasdaq: AKBA), a biopharmaceutical company focused on the development and commercialization of therapeutics for patients with kidney disease, today announced...

JPM : 104.59 (+1.62%)
AKBA : 6.39 (+1.43%)
Akebia Therapeut Rises 10.46% on Heavy Volume: Watch For Potential Pullback

Akebia Therapeut (NASDAQ:AKBA) traded in a range yesterday that spanned from a low of $8.91 to a high of $10.45. Yesterday, the shares gained 10.5%, which took the trading range above the 3-day high...

AKBA : 6.39 (+1.43%)
Akebia Therapeutics and Keryx Biopharmaceuticals Complete Merger, Creating Fully Integrated Renal Company

Akebia Therapeutics, Inc. (Nasdaq:AKBA) and Keryx Biopharmaceuticals, Inc. today announced the successful completion of their previously announced merger.

AKBA : 6.39 (+1.43%)
Stemline Therape is Among the Companies in the Biotechnology Industry with the Best Relative Performance (STML , UTHR , AKBA , XON , AGIO )

Here are the top 5 stocks in the Biotechnology industry ranked by performance. We compiled the trading activity from yesterday and then analyzed the industry looking for stocks that were outperforming....

STML : 10.68 (+4.91%)
AKBA : 6.39 (+1.43%)
UTHR : 115.75 (+1.37%)
Keryx Biopharmaceuticals Stockholders Approve Merger with Akebia Therapeutics

Keryx Biopharmaceuticals, Inc. (Nasdaq: KERX), a biopharmaceutical company focused on bringing innovative medicines to people with kidney disease, today announced that Keryx stockholders voted in favor...

KERX : 3.36 (-2.04%)
AKBA : 6.39 (+1.43%)
Akebia Therapeutics Shareholders Approve Merger with Keryx

Akebia Therapeutics, Inc. (Nasdaq:AKBA) today announced that Akebia shareholders voted to approve the share issuance proposal required to complete the merger with Keryx Biopharmaceuticals,...

KERX : 3.36 (-2.04%)
AKBA : 6.39 (+1.43%)
Corelogic Inc Has Returned 24.8% Since SmarTrend Recommendation (CLGX)

SmarTrend identified a Downtrend for Corelogic Inc (NYSE:CLGX) on July 26th, 2018 at $51.30. In approximately 4 months, Corelogic Inc has returned 24.83% as of today's recent price of $38.56.

CTT : 8.47 (-0.24%)
EPAY : 50.00 (+0.62%)
EXAS : 78.80 (+4.19%)
WYNN : 115.18 (+0.80%)
HMSY : 29.58 (+0.34%)
GLT : 11.97 (+3.19%)
MHK : 126.62 (+1.96%)
BBW : 5.14 (+3.21%)
CDW : 81.69 (+1.15%)
COUP : 76.66 (+4.13%)
QTWO : 56.02 (+2.45%)
DENN : 18.16 (+0.55%)
MYL : 29.59 (+0.14%)
DFRG : 8.17 (-0.12%)
GCAP : 6.51 (-0.31%)
FEYE : 16.43 (+1.67%)
MXIM : 53.61 (+1.71%)
POL : 31.65 (+2.06%)
AN : 37.92 (+0.64%)
TWO : 14.13 (+0.36%)
HUBG : 43.87 (+4.25%)
AR : 10.82 (+0.56%)
RE : 216.69 (+0.63%)
NNBR : 8.46 (-0.47%)
ARE : 124.26 (+1.23%)
CVI : 39.39 (+3.36%)
CERS : 5.68 (+0.53%)
NDAQ : 83.14 (+0.85%)
ELLI : 73.11 (+4.20%)
BLDR : 12.52 (+0.16%)
EGRX : 44.40 (+1.93%)
RGLD : 82.37 (-0.56%)
PRGO : 45.97 (+2.45%)
PENN : 24.60 (+1.03%)
NTAP : 62.98 (+1.71%)
IBM : 123.82 (+1.33%)
NTRI : 43.54 (-0.32%)
BANR : 56.29 (+1.97%)
CWT : 47.24 (+0.98%)
STAA : 35.16 (+1.88%)
ATHN : 133.83 (+0.18%)
CL : 62.63 (+1.02%)
TFSL : 16.73 (+0.24%)
UFPI : 29.29 (+0.34%)
SDRL : 9.85 (+3.47%)
GOV : 6.87 (-5.50%)
HQY : 61.22 (+5.23%)
IPGP : 132.51 (+2.55%)
MINI : 36.62 (unch)
CMTL : 25.65 (+1.95%)
CHD : 68.36 (+1.44%)
GPI : 61.38 (+1.56%)
HRL : 43.84 (+1.13%)
RARE : 53.34 (+3.47%)
MLI : 25.24 (+1.73%)
GPS : 26.01 (+1.64%)
CHS : 6.20 (+1.31%)
RYAM : 13.44 (+0.22%)
PBI : 7.15 (-1.92%)
NUVA : 48.02 (+2.43%)
IMDZ : 1.42 (+1.43%)
CAMP : 13.99 (-0.14%)
NOC : 267.75 (+1.39%)
AEL : 30.91 (+0.39%)
EBIX : 54.29 (+4.18%)
DISCA : 27.71 (+1.50%)
GPOR : 9.25 (+4.88%)
BGS : 28.51 (-2.50%)
TECH : 163.17 (+0.75%)
PCH : 35.39 (+1.29%)
NOV : 30.45 (+2.22%)
TECD : 93.23 (+0.34%)
DISCK : 25.92 (+1.73%)
DECK : 118.87 (+1.11%)
NOW : 190.09 (+1.91%)
MGLN : 62.34 (+0.23%)
IEX : 140.77 (+2.13%)
PTC : 87.68 (+0.15%)
AVT : 42.49 (+1.58%)
RGS : 19.06 (+0.32%)
BSFT : 54.95 (+0.09%)
FOSL : 18.00 (unch)
WAL : 45.32 (+2.19%)
IVR : 15.77 (+0.45%)
ENR : 46.84 (+0.02%)
ISBC : 11.84 (+0.25%)
SHOO : 32.16 (+1.04%)
HDP : 14.68 (+1.80%)
AWK : 92.61 (+0.05%)
OMED : 0.79 (+5.05%)
LADR : 16.52 (-0.72%)
BIG : 31.88 (+0.98%)
WY : 25.08 (+1.79%)
JBLU : 17.60 (+0.86%)
GNMK : 6.01 (+1.01%)
FORM : 13.87 (+2.06%)
PFSI : 20.71 (-0.29%)
NEWM : 13.25 (-0.60%)
KFRC : 32.84 (+0.12%)
HOLX : 44.12 (+2.37%)
TMK : 81.98 (+0.34%)
AXTA : 25.57 (+1.43%)
PGEM : 21.65 (unch)
CLH : 57.34 (+1.59%)
CLI : 20.56 (+0.19%)
NRG : 40.34 (-1.75%)
CLGX : 36.56 (+1.75%)
SFLY : 44.53 (+1.76%)
ICUI : 238.09 (+1.97%)
CARA : 15.35 (-0.26%)
WTR : 34.08 (-0.26%)
NTGR : 38.47 (+1.96%)
OLED : 100.01 (+2.68%)
VNDA : 31.05 (+0.75%)
HIBB : 15.68 (+1.42%)
FFBC : 26.33 (+1.23%)
DLTR : 94.66 (+0.10%)
EQT : 21.18 (+1.05%)
OMER : 13.43 (+3.79%)
KTOS : 14.63 (+3.39%)
SRCL : 41.77 (+2.03%)
GES : 22.13 (+2.98%)
KMX : 61.92 (-4.09%)
PLAB : 10.27 (+0.49%)
NCS : 7.86 (+4.38%)
MAR : 109.05 (+0.53%)
MRVL : 16.88 (+2.18%)
UAL : 85.59 (-1.33%)
CNK : 40.92 (+1.49%)
NATH : 73.22 (+1.65%)
TPH : 12.54 (-0.24%)
OCUL : 3.94 (-0.25%)
SKYW : 49.59 (+2.27%)
HIVE : 3.46 (-0.86%)
GAIA : 11.21 (+0.18%)
ESRX : 92.33 (-3.62%)
PHM : 26.59 (-0.97%)
EBS : 62.34 (-0.42%)
CACI : 154.93 (+0.89%)
SAVE : 59.36 (-1.58%)
EZPW : 9.25 (+3.35%)
TPX : 52.47 (+0.65%)
KLAC : 95.73 (+3.02%)
ULTA : 291.50 (+2.68%)
WWE : 83.43 (+2.18%)
ESV : 4.63 (+4.04%)
LTRPA : 17.39 (+0.29%)
DAL : 48.11 (-0.23%)
BMY : 50.12 (+1.05%)
ECL : 154.50 (+1.30%)
CHRW : 88.67 (+3.06%)
WWW : 33.29 (+0.70%)
ETH : 18.67 (+0.05%)
IART : 47.04 (+1.47%)
LE : 17.35 (+6.64%)
LH : 137.70 (+1.80%)
HZO : 20.20 (-3.21%)
MTD : 602.10 (+2.45%)
OSTK : 15.13 (+11.17%)
LDOS : 56.88 (+1.43%)
SAGE : 139.79 (+2.44%)
CIEN : 38.50 (+1.21%)
MTW : 16.13 (+4.54%)
AMC : 14.46 (+2.48%)
NDLS : 7.56 (+2.16%)
EFII : 24.45 (+3.87%)
SIVB : 230.99 (+2.49%)
MU : 35.76 (+5.55%)
DSW : 27.15 (+1.23%)
VRNT : 46.58 (+0.37%)
OII : 15.90 (+1.86%)
SAFM : 120.81 (+6.58%)
DATA : 123.68 (+1.98%)
TLYS : 12.05 (+0.58%)
TREE : 288.46 (+0.30%)
TRUP : 28.14 (+0.86%)
AMCX : 63.84 (+0.50%)
EXPD : 69.29 (+1.99%)
SUPN : 38.05 (+2.40%)
NBIX : 91.53 (+3.31%)
SAIC : 66.01 (+0.55%)
CBM : 43.54 (+2.06%)
BURL : 169.47 (+0.92%)
AMED : 127.12 (+0.18%)
EXPR : 5.40 (+1.89%)
SBH : 18.08 (+2.26%)
ATSG : 24.21 (+2.24%)
PLT : 36.08 (-1.90%)
QDEL : 52.99 (+1.44%)
NLNK : 1.52 (+0.66%)
STMP : 175.85 (+2.43%)
IPCC : 142.80 (+0.32%)
BMTC : 38.00 (+1.01%)
STML : 10.68 (+4.91%)
EGL : 29.10 (+0.24%)
LUV : 51.57 (+1.94%)
CCL : 54.88 (+2.50%)
INOV : 14.46 (-1.43%)
COTY : 7.53 (+1.35%)
MGM : 28.56 (+2.96%)
AKBA : 6.39 (+1.43%)
LGIH : 55.60 (-1.21%)
CDNS : 46.62 (+1.92%)
CRZO : 12.53 (+5.56%)
TEN : 34.59 (+3.35%)
HAIN : 18.56 (+1.14%)
Akebia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Akebia Therapeutics, Inc. (Nasdaq:AKBA), a biopharmaceutical company focused on delivering innovative therapies to patients with kidney disease through the biology of hypoxia-inducible...

AKBA : 6.39 (+1.43%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 24% Sell with a Weakening short term outlook on maintaining the current direction.

Longer term, the trend strength is Average. Long term indicators fully support a continuation of the trend.

See More Share

Trade AKBA with:

Business Summary

Akebia Therapeutics Inc. is a biopharmaceutical company. It focuses on the development and commercialization of proprietary therapeutics based on hypoxia inducible factor biology for patients with kidney disease. Akebia Therapeutics, Inc. is headquartered in Cambridge, Massachusetts.

See More

Key Turning Points

2nd Resistance Point 6.74
1st Resistance Point 6.57
Last Price 6.39
1st Support Level 6.20
2nd Support Level 6.00

See More

52-Week High 15.78
Fibonacci 61.8% 11.74
Fibonacci 50% 10.49
Fibonacci 38.2% 9.24
Last Price 6.39
52-Week Low 5.20

See More

Add Data Columns to this Table
Learn about our Custom Views
Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Read About Upcoming
Changes to This Feature
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar